Editas Medicine Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (43)

Latest Posts

About This Stock More About This Stock
The Best Dressed Chart Patterns Of 2020 - Part I
Article By: Macro-Ops
Sunday, January 3, 2021 2:24 AM EST
Our goal for the year was simple: Identify and trade the best-looking classical chart set-ups. We've broken it into sections by chart pattern and the best set-ups in those patterns.
In this article: LGND, AEO, NLS, NYT, WLK, DMTK, LB, AMRK, ICBK, EDIT, CINR, AIH, HPR, TBIIF, CELH, PTON Also: VOLVF
Read
Top ETF Of December & Its Best Stocks
Article By: Sweta Killa
Thursday, December 24, 2020 4:58 PM EST
Although most of the stocks in the ARKG fund’s portfolio delivered strong returns, a few gained at least 80% last month. Here are the five best-performing stocks in the ETF with their respective positions in the basket.
In this article: BEAM, PACB, EDIT, SYRS, AQB Also: ARKG
Read
Editas Medicine: CRISPR Gene Editing Leader
Article By: GreenDotStocks
Wednesday, November 11, 2020 9:35 AM EST
Editas is focused on the CRISPR gene-editing technology, which promises solutions to hereditary and chronic diseases. An exciting story, but is it investable?
In this article: EDIT
Read
7 Disruptive Innovation Stocks - Price Technical Analysis
Video By: Peter Mathers
Sunday, October 11, 2020 9:28 PM EST
I'm looking at the price technicals for these US Stocks: Deere & Co, Docusign, Editas Medicine, Elbit Systems, Evogene, Faro Technologies, and Fate Therapeutics.
In this video: DE, ESLT, EVGN, EDIT, DOCU, FARO, FATE
Watch
Biotech Stock Playbook In A Choppy Momentum Market
Article By: Rod Raynovich
Tuesday, September 29, 2020 4:57 AM EST
Biotech stocks peaked in mid-July but we have assumed a fourth quarter rally driven by clinical news in oncology and important scientific breakthroughs in diagnostic testing for coronavirus and COVID vaccine data.
In this article: ABT, AZN, BMY, GSK, JNJ, MRK, RHHBY, GNMK, NVAX, OSUR, QDEL, HOLX, PACB, ABBV, AXDX, EDIT, CRSP
Read

Latest Tweets for $EDIT

No tweets yet!

$EDIT

Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Michael Molman 12/6/2017 5:41:11 PM

Looking forward to hearing more information about $EDIT. Company seems to operate in a very exiting and potentially fast growing new field.

1 to 1 of 1 comments